About Binnopharm Group

A Top 3 Russian pharmaceutical company in the domestic market*
PHARMACEUTICAL COMPANY

that includes five manufacturing facilities across Russia. The Group produces medicines in various dosage forms (including those from Binnopharm Group’s own active pharmaceutical ingredients), polymer-based medical products, and veterinary medicines.

Binnopharm Group’s drug portfolio is one of the largest in the Russian pharmaceutical market and includes generic and original drugs.
450+
marketing
authorisations
100+
medicines included in in the List of Vital and Essential Medicines
200+
pharmacological
 groups
Extensive expertise, cutting-edge technology, diversified and well-balanced product portfolio, wide footprint, and dynamic growth in the inpatient and retail segments of domestic and foreign pharmaceutical markets are the Group’s key competitive advantages.
Binnopharm Group is one of the largest suppliers for the inpatient segment, providing clinics and hospitals with antibiotics in various dosage forms; medicines for endocrinology, neurology, cardiology and other therapeutic groups; and medical devices for blood transfusion.
In the retail segment, Binnopharm Group is represented by renowned branded medicines and INN generics. The Company's products dominate respective sectors in terms of sales volumes.
A team of medical and pharmaceutical representatives help promote our products across all of Russia.
Binnopharm Group’s products are also available in 14 countries.
The Group manufactures up to 500 million units of quality medicines annually
Human capital development along with constant upgrades of production capacities, improvement of R&D competencies, and adherence to the world's top quality control standards is what underpins Binnopharm Group’s operations.

Leadership

Binnopharm Group's senior executives are a team of professionals with many years of industry experience who leverage their knowledge and expertise to help the Company grow and evolve.
Rustem Muratov
Rustem Muratov
Chief Executive Officer, member of the Board of Directors of Binnopharm Group
Ekaterina Slavgorodskaya
Sales and Promotion Director
Alexey Chupin
Research and Registration Director
Elina Bagautdinova
Chief Financial Officer
Igor Petrov
Director for Corporate Governance and Business Transformation
Anna Fomina
Director for Foreign Economic Activities
Maria Bogomolova
Marketing Director
Tatiana Fedchenko
HR & Organisational Development Director
Elena Shipilova
Chief Communications Officer
Sergey Komarov
Director for Planning and Business Analysis
Valery Oratovsky
Director for Tender and Procurement Activities
Svetlana Bolsheva
Director for Strategy and Business Development
Anton Kozlov
Internal Audit Director
Evgeny Zaytsev
Director for IT and Automation of Business Processes
Dmitry Zubov
Dmitry Zubov
Chairman of the Board of Directors of Binnopharm Group,
Chairman of the Board of Centrosoyuz
Vyacheslav Vorobyev
Vyacheslav
Vorobyev
Chairman of the Board of Directors of the Kama Group of Companies
Artyom Zasursky
Artyom
Zasursky
Vice President for Strategy and Development of Sistema
Oleg Mubarakshin
Oleg
Mubarakshin
Managing Partner of Sistema
Rustem Muratov
Rustem
Muratov
Chief Executive Officer of Binnopharm Group
Yuri Kalinin
Yuri
Kalinin
President of the Russian Union of Associations and Enterprises of the Pharmaceutical and Medical Industry; Chairman of the Commission on the Pharmaceutical and Medical Industry
Stepan Natalevich
Stepan
Natalevich
Executive Director of VTB Capital
Alexander Shevchuk
Alexander
Shevchuk
Executive Director of the Association of Institutional Investors
Nelly Naigovzina
Nelly
Naigovzina
Professor, Head of the Department of Public Health and Healthcare at A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Alexander Gintsburg
Alexander
Gintsburg
Director of the Gamaleya Research Institute of Epidemiology and Microbiology, member of the Russian Academy of Sciences, expert in molecular biology and the development of biotech products, including a COVID-19 vaccine
Olga Ryzhkova
Olga
Ryzhkova
Director of the Investment Department of the Russia-China Investment Fund

Our history

Binnopharm Group began its operations in the Russian market following the merger of Sistema’s pharmaceutical assets in 2020. Boasting extensive experience and history, the Company has a number of manufacturing facilities, the largest of which was built in 1958. The Group’s newest plant came on stream in 2019.
1958
Established as an active pharmaceutical ingredients and antibiotic manufacturer.
1970
First batches of Biomycin produced.
1980
Start of veterinary medicines production.
2000
Product portfolio expanded from 40 medicines to 200. Sintez begins manufacturing new dosage forms: capsules, ointments, drops, etc.
1991
Established as a producer of immunobiological medicines.
2002-2004
Major overhaul of production. Launch of full-cycle manufacturing of solid dosage forms.
2013
Evolution into the only manufacturer in Russia to have an approved vendor status issued by the World Health Organisation.
1994
Founded on the basis of the Research Institute of Applied Microbiology.
2010
Major overhaul of production. Launch of full-cycle manufacturing of solid dosage forms.
2019
Launch of a new production facility. 3x increase in the plant's capacity.
2006
Founded by Sistema as a full-cycle biopharmaceutical company.
2009
Market launch of Regevac B, a hepatitis vaccine. Production of medicines across the key therapeutic groups.
2010
Created as an infusion solutions manufacturer.
2013
Merger of Binnopharm and Alium.
2019
Sistema's acquisition of Sintez and Biocom.
2019
Sistema's acquisition of Obolenskoe.
Merger with Binnopharm.
2020
Launch of Gam-COVID-Vac (Sputnik V) manufacturing.
2020
Sistema consolidates its pharmaceutical assets under Binnopharm Group.
*according to AlphaRM